

DOI: 10.21767/2574-2817.100034

High IgG1 Malaria Antibodies Level in Children is a Possible Risk Factor of Blackwater Fever: A Case-Control Study

Joseph M Bodi¹, Célestin N Nsibu¹, Roland L Longenge¹, Michel N Aloni², Pierre Z Akilimali³, Pierre M Tshibassu⁴, Patrick K Kayembe³, Ahmeddin H Omar⁵, Kenji Hirayama⁶, Jan Verhaegen⁷, Aimé Lumaka^{8,9*} and Prosper T Lukusa⁸

¹Department of Pediatrics, Emergency and Intensive Care Unit, University Hospital of Kinshasa, University of Kinshasa, DR Congo

²Department of Pediatrics, Haemato-Oncology and Nephrology Unit, University Hospital of Kinshasa, University of Kinshasa, DR Congo

³Division of Biostatistics and Epidemiology, School of Public Health, University of Kinshasa, DR Congo

⁴Department of Pediatrics, Gastroenterology and Neurology Unit, University Hospitals, University of Kinshasa, DR Congo

⁵Division of Malaria Control (DOMC), Ministry of Health, Nairobi, Kenya

⁶Department of Immunogenetics, Institute of Tropical Medicine (Nekken), University of Nagasaki, Japan

⁷Department of Microbiology, Katholieke Universiteit Leuven, Leuven, Belgium

⁸Center for Human Genetics, Department of Pediatrics, University of Kinshasa, DR Congo

⁹Department of Biomedical and Preclinical Sciences, GIGA-R, Laboratory of Human Genetics, University of Liège, Belgium

*Corresponding author: Aimé Lumaka, Department of Biomedical and Preclinical Sciences, GIGA-R, Laboratory of Human Genetics, University of Liège, Belgium, E-mail: aime.lumaka@uliege.be

Received date: August 18, 2018; Accepted date: November 22, 2018; Published date: November 30, 2018

Copyright: © 2018 Bodi JM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Citation: Bodi JM, Nsibu CN, Longenge RL, Aloni MN, Akilimali PZ, et al. (2018) High IgG1 Malaria Antibodies Level in Children is a Possible Risk Factor of Blackwater Fever: A Case-Control Study. Ped Health Res Vol.3 No.3:9.

Abstract

Context: Pathogenesis of acute massive intravascular hemolysis in Blackwater fever is very complex. Mostly, Malaria immunity deficiency in expatriates, Quinine and Plasmodium are incriminated. The possible role of malaria IgG1 antibodies in BWF is not fully elucidated.

Objectives: This study aimed to determine the profile of malaria IgG1 for malaria crude antigen in children developing blackwater fever compared to patients with uncomplicated malaria

Methods: This case-control study was conducted in 4 medical institutions across Kinshasa. Cases were patients with Blackwater fever (BWF) whereas controls had uncomplicated *Plasmodium falciparum* malaria (UM). For each case, 2 controls were recruited and were matched for age, sex and the area of residence. Malaria IgG1 were assessed by standard ELISA and absorbance measured in an automated plate reader.

Results: The majority of BWF cases (81.4%) were above 5 years old while only 18.6% were aged below 5 (OR: 1.33; 0.53-3.32). The level of malaria IgG antibodies in BWF children were significantly higher compared to uncomplicated malaria (p=0.002). Quinine was used by 95.3% of the BWF cases ([OR: 50.19 (10.75-234.42)] p<0.001) versus in uncomplicated malaria. There was no

linear correlation between the age of patients and the logarithm of antibodies. R2 is totally null (p=0.335).

Conclusion: Malaria IgG1 antibodies is significantly elevated in children with BWF and could trigger the occurrence of BWF. The absence of correlation with age suggests that BWF could not be age dependent.

Keywords: Black-water fever; IgG; Antibodies; Malaria; Congo

Introduction

Pathogenesis of acute massive intravascular hemolysis in Blackwater fever (BWF) is recognized to be very complex. Deficiency in malaria immunity often observed in the expatriate population, Quinine treatment and Plasmodium falciparum parasite are the most commonly incriminated factors [1-3]. It is likely that all these factors interact with some underlying genetic factors for the development of the BWF [4]. It was previously observed that BWF occurred during *P. falciparum* malaria episodes in individuals receiving quinine [3], prompting further investigations of the role of the parasite and that of the quinine compound in the occurrence of BWF [2,5-9]. It has also been reported that the complex, that is made up by Quinine the *P. falciparum* Parasite and the Red blood cell, alters the red blood cell membrane and acts as a neo-antigen, triggering the synthesis of antibodies. Future contacts between these

antibodies and neo-antigen will result in intravascular acute massive hemolysis. This reaction is attributed to complement activation through either the classical pathway or the alternative pathway [10-14].

Malaria antibodies increase gradually with age in autochthone population, due to sustained contacts with the vector and malaria parasite [15-30]. This elevation is a more complex process that can be divided into few steps. Children aged below 6 months are under a protection provided to them by maternally transmitted antibodies, fetal hemoglobin, the low concentration of Para Amino Benzoic Acid contained in maternal breast milk, and the use of the insecticide-treated net (INT). Later, children between 6 months and 5 years lose most of these protective factors and become exposed to malaria attacks. This vulnerability is confirmed by the occurrence of about 90% of malaria gross mortality during this time window [31]. Finally, after 5 years of age, children develop acquired protective malaria immunity and clinical malaria episodes decrease both in frequency and severity [31-33].

Regarding the specific aspects of this malaria immunity, IgG1 directed against Apical Membrane Antigen 1 (AMA1) and the carboxy-terminal region of the Merozoite Surface Protein 1 (MSP1-19), are predominant in malaria immunity protection during the first 2 years of life [28,29,34]. From the 3rd year of the life, malaria IgG3, directed against MSP2, increase [28,34]. Basically, the role of these antibodies is to protect against malaria episodes. Surprisingly, the majority of children with BWF are above 5 years, an age where children are expected to have already acquired protective immunity against malaria in the stable endemic area [5,6,35,36]. To date, the amounts of these malaria antibodies have not been evaluated in a systematic way in BWF patients. Also, the possibly perverse effect of malaria antibodies in the occurrence of BWF is not fully elucidated. This study aimed at determining the profile of malaria IgG1 antibodies in children with blackwater fever compared to patients with uncomplicated malaria.

Methods

Study design, subjects, and case definitions

This is a case-control study carried out in four medical institutions across Kinshasa, between January 2010 and December 2011. The 2-years study period was necessary to gather sufficient patients. Kinshasa, the capital of DRC, is characterized by two distinct seasons, a rainy season (mid-September to mid-May) and a dry season (mid-June to mid-August). Cases are patients with Blackwater Fever (BWF), whereas controls had uncomplicated *Plasmodium falciparum* malaria (UM). BWF was defined as the presence of hemoglobin in the dark urine after acute intravascular hemolysis (macroscopic hemoglobinuria). In addition, cases were febrile patients, with jaundice, anemia and *Plasmodium falciparum* malaria confirmed by the presence of *P. falciparum* parasite on blood thick and film. Conversely, Uncomplicated Malaria (UM) were patients with fever associated with the presence of *P. falciparum* on blood thick and film. Consecutively to the recruitment of a case, two controls were recruited, matching for

gender, age and residential area to the case. The mean age was 8.62 ± 3.84 years for cases and 8.55 ± 3.77 years for controls. The range was 2-15 years in the two groups.

Clinical evaluation

A standard clinical examination was conducted to obtain a medical history and clinical data. Malaria was confirmed by the presence of the parasite in malaria blood thick and film.

Laboratory measurements

Twenty mL of fresh urine were collected from each participant. The presence of hemoglobin in urine was first accessed by urinary dip stick (Medi test Combi9, Machery Eur, Paris, France) and then confirmed by a spectrometer (Thermo Genesis 10 BIO, New York USA) using 3,3' dimethyl benzidine reagent and protocol [37].

Collection of blood

Sera were collected in small cryotubes of 2 ml, and then stored at -80 Celsius degrees (°C) in the laboratory of Department of Tropical Medicine, school of medicine at the University of Kinshasa. Later, these samples were transferred to the Institute of Tropical Medicine at Nagasaki University in Japan for immunological analysis. Before the shipment to Nagasaki, samples were taken out of the -80°C storage; each individual tube was stored in an absorbing pouch accordingly labelled with the patient's ID. Next, these pouches were stored in (UN code UN3373 biology substance category B) boxes following the P650 packing instructions. The box was picked-up from our University in Kinshasa, transported and delivered at the Nagasaki University, Japan by DHL company. Samples were shipped through standard DHL cold transport chain.

Quantification of malaria antibodies IgG1

Malaria Immunoglobulins (IgG1) were assessed from the individual sera by ELISA. Briefly, 96-well plates were pre-coated with 100 µl of 0.1 µg/ml of *Plasmodium falciparum* crude antigen in coating buffer and kept overnight at 4°C. Plates were washed three times with 400 µl/well of 0.05% Tween-PBS, then blocked for nonspecific binding using 340 µl/well of 0.1% blocking reagent (Roche Diagnostics, Mannheim, Germany) for 1h at 37°C. Plates were washed three times with 400 µl/well of 0.05% Tween-PBS, then 100 µl of serially diluted sera (1:10) was added and incubated at 37°C for 3h. Plates were then washed five times with 400 µl/well of 0.05% Tween-PBS and 100 µl of Horseradish Peroxidase (HRP)-conjugated goat anti-human IgG1 (Southern Biotechnology, Birmingham, AL), diluted with blocking buffer (1:4000), was added and incubated for 1 h at room temperature. Plates were washed 5 times with 400 µl/well of 0.05% Tween-PBS and the antigen-antibody reaction was visualized by the addition of 50 µl/well of 3,3',5,5'-tetramethylbenzidine (TMB) (Vector Laboratories, CA, USA). The color development reaction was stopped after 30 min by adding 50 µl of 1N of H₂SO₄, and the absorbance was measured in an automated plate reader (Bio-Rad, Hercules, CA) at 450 nm [38].

Ethics statement

Written informed consent was obtained from parents for each patient and the study protocol conforms to the ethical guidelines of the World Medical Association Declaration of Helsinki-Ethical Principles for Medical Research Involving Human Subjects. The study received approval of Ethics Committee of Public Health School of University of Kinshasa under the number ESP/CE/027B/2011. Patient's information was obtained using anonymized research forms designed in local languages.

Data management and analysis

Data were recorded using Epi-Info 7 Version 2002 (CDC) and analyzed using SPSS 18.0. The geometric mean of malaria antibodies with his confidence interval was calculated. After geometric mean calculation, data were transformed into logarithm of antibodies. The error of mean with confidence interval were calculated and allowed comparison with the logarithm of antibodies in the 2 groups. The simple linear regression was used to analyze the correlation between the logarithm of antibodies and age of children in the two groups.

Ancova model allowed modeling the logarithm of antibodies and age in months between cases and controls. All the tests were calculated at 5% significance. Descriptive analysis was performed to obtain either means for quantitative variables or proportions for all the qualitative variables. The confidence interval at 95% was calculated.

Multivariate analysis was used to determine associations between variables and BWF. The odds ratio was used to measure the force of associations.

Results

A total of 129 children, 43 with BWF and 86 with UM were recruited in the study. Sixty-eight (52.7%) females and 61 (47.3%) males were included with a male to female sex-ratio of 1:1.1 and the age ranging from 2 to 15 years with a mean age of 8.57 ± 3.73 years. The mean age was 8.62 ± 3.84 years for patients with BWF or 8.55 ± 3.77 years for UM. In total, 81.4% of children with BWF were over 5 years of age, while only 18.6% under 5 years old [OR: 1.33 (0.53-3.32) (**Table 1**).

Table 1. Sociodemographic features of children with BWF versus UM.

Variables	Case (n=43)	Controls (n=86)	Total (n=129)	OR (IC95%)	p
Distribution for age					
- ≤ 5 years	8 (18.6)	20 (23.3)	28 (21.7)	1	0.676
- > 5 ears	35 (81.4)	66 (76.7)	101 (78.3)	1.33 (0.53-3.32)	
Sex: n(%)					
- Male	21 (48.8)	40 (46.7)	61 (47.3)	1.10 (0.53-2.28)	0.803
- Female	22 (51.2)	46 (53.5)	68 (52.7)	1	
Season					
- Rainy	38 (88.4)	51(59.3)	89 (69.0)	5.22 (1.87-14.56)	<0.001
- Dry	5 (11.6)	35 (40.7)	40 (31.0)	1	
Plasmodium					
- Falciparum	37 (86.0)	73 (84.9)	110 (85.3)	1.10 (0.39-3.12)	0.86
- Falciparum-malariae	6 (14.0)	13 (15.1)	19 (14.7)	1	
Parasitemia (per microliter)					
- Low<500/μL	32 (78.0)	43 (51.8)	76 (61.3)	3.31 (1.41-7.78)	0.005
- High> 500/μL	9 (22.0)	40 (48.2)	48 (38.7)	1	

Interestingly, 6 (14%) had co-infection of *P. falciparum* and *Plasmodium malariae* while 37 (86%) have mono-infection. Likewise, 73 children (84.9%) in the control group had mono-infection with *P. falciparum*, while 13 children (15.1%) in this group had co-infection with *P. falciparum* and *P. malariae*. Low parasitemia was mostly observed in BWF children. The association shows a statistically significant difference 331(141-778) with $p=0.005$ (**Table 1**).

In univariate analysis, using crude Odds ratio, quinine was significantly associated with the occurrence of BWF [OR:47.31 (10.64-210.3), $p<0.001$] (**Table 2**). Interestingly, in multivariate analysis, using adjusted Odds Ratio, quinine was associated with the occurrence of BWF with $p<0.001$ [OR: 50.19 (10.7-234.4)].

The geometric mean of antibodies in the study population was high in Blackwater fever children; [1.95 (IC95%: 1.55-2.44)] versus in control group: [1.19 (IC95%: 0.98-1.002.0)]. The curve

of antibodies in BWF group was significantly higher compared to that of antibodies in UM group (**Figure 1**).

Table 2. Determinants factors in the occurrence of BWF.

Variables	Crude OR		adjusted OR	
	(95% IC)	p	(95% IC)	p
Antimalaria drugs				
- ACT	1	<0.001	1	<0.001
- Quinine	47.3 (10.6-210.3)		50.19 (10.7-234.4)	
G6PDstatus				
- Normal ($\geq 276\text{UI/L}$)	1	0.017	1	0.115
	0.35 (0.14-0.54))		0.39 (0.12-1.27)	
Parasitemia				
- High > 500/ μL	1	0.005	1	0.012
- Low < 500/ μL	0.30 (0.13-0.71)		0.25 (0.08-0.74)	




Figure 1. Antibodies curves in BWF and UM children: The curve of antibodies in BWF group was significantly higher compared to that of antibodies in UM group.

Regarding the evolution of antibodies and age of patients, there was no linear correlation between the age of patients and the logarithm of antibodies. Age alone did not influence directly the rate of antibodies ($p=0.349$). The coefficient of R^2 was totally null and this relation was not linear (**Figure 2**).

Among the hemoglobinuria patients, seven (16.2%) developed Acute Renal Failure (ARF) when the other did not. Due to financial constraints, only two children among those seven with ARF received peritoneal dialysis whereas others received other medication-based conservative treatments. In the evolution, three of the patients with ARF who did not receive dialysis developed anuria and died from this complication.




Figure 2. Correlation between logarithm of antibodies and age of patients. Note: there was no linear correlation between the age of patients and the logarithm of antibodies (($p=0.349$). R^2 almost null).

Discussion

Malaria is still one of the deadliest diseases in children in Sub-Saharan African countries and it takes various deadly presentations including BWF. We conducted a case-control study to investigate the possible association between IgG1 against malaria parasite and the occurrence of BWF in children from DR Congo.

We included both small children and young adolescents but observed no significant association between the age and the risk for BWF. A great proportion of individuals infected by more than one species of malaria parasite was noticed in this study. However, there was no significant change in the risk for BWF between those with only *P. falciparum* and those with both *P. falciparum* and *P. malariae*.

It is widely known that acquired immunity establishes with age and is triggered by exposition to pathogen among other factors. Of note, people living in the high malaria transmission area, where host-pathogen interactions are sustained, develop malaria immunity early in life. In this setting, children from around 5 years already have established acquired immunity against malaria, thus exhibit a significant decrease of malaria episodes [19-33]. During the first two years of life, malaria IgG1 antibodies, directed against AMA1 and MSP1-19, are gradually elevated [28,29,34]. These IgG1 remain predominant till around the age of 10 when IgG3 targeting MSP2, which start increasing from 3 years of age, take over. Local studies confirmed this antibody conversion and showed high parasitemia around 10 years old [39,40]. No linear correlation was observed between the age of patients and the values of IgG1 antibodies in the current study. A larger cohort will be useful to verify this correlation. It should, however, be mentioned that many other factors are involved in the acquisition of immunity like the duration of exposure to the vector, the nature of *P. falciparum* antigen involved, the vector, the immune and genetic status of the patients [23,25,28,41,42], which were beyond the scope of this study.

Previous studies [25] suggested a slight association between total malaria IgG and the malaria prevalence, which in turn is known to be varied depending on the weather seasons. In this study, patients were recruited over 2 years, during 2 rainy seasons and 2 dry seasons. BWF was significantly observed during rainy seasons (**Table 1**), known as the high malaria prevalence season. However, we did not investigate the association between IgG and the seasonal prevalence of malaria.

Malaria IgG1 are known to be anti-parasitemia and expected to be observed in combination with low parasitemia, whereas malaria IgG3 antibodies are not anti-parasitemia and can explain the high parasitemia. This has been proven in children above 5 years as well as an expatriate, both found to develop acute massive intravascular hemolysis in the presence of high malaria antibodies IgG1 and low parasitemia [43]. Likewise, our result also shows that malaria IgG1 was significantly elevated in BWF patients. It should be noted that the elevated IgG1 levels did not protect them against BFW. Malaria IgG1 may probably be involved in the pathogenesis of the disease.

To be consistent with the high IgG1 values, one would expect parasitemia to be lower in patients with established acquired immunity against malaria. Many studies have reported low parasitemia in BWF patients [44]. We now report hereby that Congolese patients presenting with BWF have low parasitemia compared to those with uncomplicated malaria. High levels of IgG1 can, of course, explain the observed low parasitemia. However, other external factors specific to our countries such as the use of anti-parasitemia nets and the regular intake of antimalarial medication can also contribute to low parasitemia. Of note, we have shown that the intake of Quinine, a popular antimalaria drug, is significantly associated with the occurrence of BWF in our cohort. Therefore, Quinine compound can explain both the low parasitemia and the BWF by acting either alone or in conjunction with IgG1 antibodies.

Peritoneal dialysis proved to be an effective treatment for those of our patients who developed Acute Renal Failure (ARF). Unfortunately, accessibility is limited to the combination of multiple factors including limited income, expensive reagent often imported from overseas countries. Luckily, a new pediatric dialysis service has been implemented and offers peritoneal dialysis at a significantly lower cost than in the past at the University hospitals in Kinshasa. Hopefully, children will receive better and quicker care to prevent the avoidable deaths as observed during our study.

Conclusion

The malaria IgG1 antibodies were very high in BWF children compared to uncomplicated malaria patients: 1.95 (IC95%: 1.55-2.44) versus 1.19 (IC95%: 0.98-1.43), $p=0.002$. The high IgG1 malaria did not protect children to develop BWF but may play important role in the activation of complement resulting in acute massive hemolysis leading to BWF. Low parasitemia was associated with the BWF children. The age alone did not influence the level of IgG1.

Limitations of the Study

Increasing sample size, measuring of malaria antibodies IgG3 and Quinine antibodies, exploring complement activation could have improved the design.

Acknowledgements

The authors are thankful to all children and parents who participated to this study, and to Nasir Nshuaib for the quantification of malaria IgG1 antibodies (department of immunogenetics, Nagasaki University, Japan). We thank all our colleagues, nurses and lab technicians involved in sample and data collection. This research project was supported by the University of Nagasaki through the Grant-in-Aid for Scientific Research (B) 17H04072(2017-2021) of KAKENHI; and the Katholieke Universiteit Leuven (Belgium) through the scholarship program for young Congolese researchers (Bourses chaires scientifiques pour jeunes Congolais). We are grateful to Prof Fons Verdonck of the KU Leuven Alumni for his support

References

1. Bruneel F, Gachot B, Wolff M, Bedos JP (2002) Blackwater fever. *Presse medicale* 31: 1329-1334.
2. Van den Ende J, Coppens G, Verstraeten T, Van Haegenborgh T, Depraetere K, et al. (1998) Recurrence of blackwater fever: triggering of relapses by different antimalarials. *Trop Med Int Health* 3: 632-639.
3. Delacollette C, Taelman H, Wery M (1995) An etiologic study of hemoglobinuria and blackwater fever in the Kivu Mountains, Zaire. *Ann Soc Belg Med Trop* 75: 51-63.
4. Ajetunmobi WA, Orimadegun AE, Brown BJ, Afolabi NK, Olabiyi FA, et al. (2012) Haemoglobinuria among children with severe malaria attending tertiary care in Ibadan, Nigeria. *Malar J* 11: 336.
5. Bodi JM, Nsibu CN, Aloni MN, Lukute GN, Kunuanuna TS, et al. (2014) Black water fever associated with acute renal failure among

- Congolese children in Kinshasa. *Saudi J Kidney Dis Transpl* 25: 1352-1358.
6. Gobbi F, Audagnotto S, Trentini L, Nkurunziza I, Corachan M, et al. (2005) Blackwater fever in children, Burundi. *Emerg Infect Dis*. 11: 1118-1120.
 7. Howard MA, Hibbard AB, Terrell DR, Medina PJ, Vesely SK, et al. (2003) Quinine allergy causing acute severe systemic illness: report of 4 patients manifesting multiple hematologic, renal, and hepatic abnormalities. *Proc* 16: 21-26.
 8. Klabunde J, Uhlemann AC, Tebo AE, Kimmel J, Schwarz RT, et al. (2002) Recognition of *Plasmodium falciparum* proteins by mannan-binding lectin, a component of the human innate immune system. *Parasitol Res* 88: 113-117.
 9. WHO, Guidelines for the Treatment of Malaria, in Guidelines for the Treatment of Malaria, Editor 2015: Geneva.
 10. Dasari P, Fries A, Heber SD, Salama A, Blau IW, et al. (2014) Malarial anemia: digestive vacuole of *Plasmodium falciparum* mediates complement deposition on bystander cells to provoke hemophagocytosis. *Med Microbiol Immunol* 203: 383-393.
 11. Dasari P, Heber SD, Beisele M, Torzewski M, Reifenberg K, et al. (2012) Digestive vacuole of *Plasmodium falciparum* released during erythrocyte rupture dually activates complement and coagulation. *Blood* 119: 4301-4310.
 12. Korir JC, Nyakoe NK, Awinda G, Waitumbi JN (2014) Complement activation by merozoite antigens of *Plasmodium falciparum*. *PLoS One* 9: e105093
 13. Pawluczko AW, Lindorfer MA, Waitumbi JN, Taylor RP (2007) Hematin promotes complement alternative pathway-mediated deposition of C3 activation fragments on human erythrocytes: potential implications for the pathogenesis of anemia in malaria. *J Immunol* 179: 5543-5552.
 14. Roestenberg M, McCall M, Mollnes TE, van Deuren M, Sprong T, et al. (2007) Complement activation in experimental human malaria infection. *Trans R Soc Trop Med Hyg* 101: 643-649.
 15. Cavanagh DR, Dodoo D, Hviid L, Kurtzhals JA, Theander TG, et al. (2004) Antibodies to the N-terminal block2 of *Plasmodium falciparum* merozoite surface protein 1 are associated with protection against clinical malaria. *Infect Immun* 72: 6492-6502
 16. Lusingu JP, Jensen AT, Vestergaard LS, Minja DT, Dalgaard MB, et al. (2006) Levels of plasma immunoglobulin G with specificity against the cysteine-rich interdomain regions of a semiconserved *Plasmodium falciparum* erythrocyte membrane protein 1, VAR4, predict protection against malarial anemia and febrile episodes. *Infect Immun* 74: 2867-2875.
 17. Polley SD, Mwangi T, Kocken CH, Thomas AW, Dutta S, et al. (2004) Human antibodies to recombinant protein constructs of *Plasmodium falciparum* Apical Membrane Antigen 1 (AMA1) and their associations with protection from malaria. *Vaccine* 23: 718-728.
 18. Aubouy A, Migot-Nabias F, Deloron P (2007) Correlations between treatment outcome and both anti-MSP119 antibody response and erythrocyte-related genetic factors in *Plasmodium falciparum* malaria. *Infect Genet Evol* 7: 147-154.
 19. Bousema T, Kreuels B, Gosling R (2011) Adjusting for heterogeneity of malaria transmission in longitudinal studies. *J Infect Dis* 204: 1-3
 20. Dodoo D, Aikins A, Kusi KA, Lamptey H, Remarque E, et al (2008) Cohort study of the association of antibody levels to AMA1, MSP119, MSP3 and GLURP with protection from clinical malaria in Ghanaian children. *Malar J* 7: 142.
 21. Fowkes FJ, Richards JS, Simpson JA, Beeson JG (2010) The relationship between anti-merozoite antibodies and incidence of *Plasmodium falciparum* malaria: A systematic review and meta-analysis. *PLoS medicine* 7: e1000218.
 22. Greenhouse B, Ho B, Hubbard A, Njama-Meya D, Narum DL, et al. (2011) Antibodies to *Plasmodium falciparum* antigens predict a higher risk of malaria but protection from symptoms once parasitemic. *J Infect Dis* 204: 19-26.
 23. Iriemenam NC, Khirelsied AH, Nasr A, ElGhazali G, Giha HA, et al. (2009) Antibody responses to a panel of *Plasmodium falciparum* malaria blood-stage antigens in relation to clinical disease outcome in Sudan. *Vaccine* 27: 62-71.
 24. Murungi LM, Kamuyu G, Lowe B, Bejon P, Theisen M, et al. (2013) A threshold concentration of anti-merozoite antibodies is required for protection from clinical episodes of malaria. *Vaccine* 31: 3936-3942.
 25. Nebie I, Diarra A, Ouedraogo A, Soulama I, Bougouma EC, et al. (2008) Humoral responses to *Plasmodium falciparum* blood-stage antigens and association with incidence of clinical malaria in children living in an area of seasonal malaria transmission in Burkina Faso, West Africa. *Infect Immun* 76: 759-766.
 26. Osier FH, Fegan G, Polley SD, Murungi L, Verra F, et al. (2008) Breadth and magnitude of antibody responses to multiple *Plasmodium falciparum* merozoite antigens are associated with protection from clinical malaria. *Infect Immun* 76: 2240-2248.
 27. Roussilhon C, Oeuvray C, Müller-Graf C, Tall A, Rogier C, et al. (2007) Long-term clinical protection from falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3. *PLoS Med* 4: e320.
 28. Stanicic DI, Fowkes FJ, Koinari M, Javati S, Lin E, et al. (2015) Acquisition of antibodies against *Plasmodium falciparum* merozoites and malaria immunity in young children and the influence of age, force of infection, and magnitude of response. *Infect Immun* 83: 646-660.
 29. Stanicic DI, Richards JS, McCallum FJ, Michon P, King CL, et al., (2009) Immunoglobulin G subclass-specific responses against *Plasmodium falciparum* merozoite antigens are associated with control of parasitemia and protection from symptomatic illness. *Infect Immun* 77: 1165-1174.
 30. Tongren JE, Drakeley CJ, McDonald SL, Reyburn HG, Manjurano A, et al. (2006) Target antigen, age, and duration of antigen exposure independently regulate immunoglobulin G subclass switching in malaria. *Infect Immun* 74: 257-264.
 31. Marsh KA, Kinyanjui S (2006) Immune effector mechanisms in malaria. *Parasite Immunol* 28: 51-60.
 32. Alles HK, Mendis KN, Carter R (1998) Malaria mortality rates in South Asia and in Africa: implications for malaria control. *Parasitology Today* 14: 369-375.
 33. WHO (2012) Malaria Policy Advisory Committee to the WHO: conclusions and recommendations of September 2012 meeting. *Malar J* 11: 424.
 34. Taylor RR, Allen SJ, Greenwood BM, Riley EM (1998) IgG3 antibodies to *Plasmodium falciparum* merozoite surface protein 2 (MSP2): increasing prevalence with age and association with clinical immunity to malaria. *Am J Trop Med Hyg* 58: 406-413

35. Bodi JM, Nsibu CN, Longenge RL, Aloni MN, Akilimali PZ, et al. (2013) Blackwater fever in Congolese children: a report of clinical, laboratory features and risk factors. *Malaria journal* 12: 205.
36. Kunuanunua TS, Nsibu CN, Gini-Ehungu JL, Bodi JM, Ekulu PM et al. (2013) Acute renal failure and severe malaria in Congolese children living in Kinshasa, Democratic Republic of Congo. *Nephrol Ther* 9: 160-165.
37. Assoumanou MG, Akpona SA (2011) Determination of urinary hemoglobin by a reagent 3,3 'dimethylbenzidine: technical development. *IJBSC* 5: 11
38. Klegerman ME, Hamilton AJ, Huang SL, Tiukinhoy SD, Khan AA, et al. (2002) Quantitative immunoblot assay for assessment of liposomal antibody conjugation efficiency. *Anal Biochem* 300: 46-52.
39. Mulumba MP, Wery M, Ngimbi NN, Paluku K, der Stuyft Van P, et al.(1990) Childhood malaria in Kinshasa (Zaire). Influence of seasons, age, environment, and family social conditions. *Med Trop* 50: 53-64.
40. Ngimbi NP, Beckers A, Wery M, (1982) Survey of the epidemiological status of malaria in Kinshasa (Republic of Zaire) in 1980. *Ann Soc Belg Med Trop* 62: 121-137.
41. Metzger WG, Okenu DM, Cavanagh DR, Robinson JV, Bojang KA, et al. (2003) Serum IgG3 to the Plasmodium falciparum merozoite surface protein 2 is strongly associated with a reduced prospective risk of malaria. *Parasite Immunol* 25: 307-312.
42. Rivera N, Romero SE, Menchaca Á, Zepeda A, García LE, et al. (2013) Blackwater fever like in murine malaria. *Parasitol Res* 112: 1021-1029.
43. McCallum FJ, Persson KE, Mugenyi CK, Fowkes FJ, Simpson JA, et al. (2008) Acquisition of growth-inhibitory antibodies against blood-stage Plasmodium falciparum. *PLoS One* 3: e3571.
44. Idro R, Aloyo J, Mayende L, Bitarakwate E, John CC, et al. (2006) Severe malaria in children in areas with low, moderate and high transmission intensity in Uganda. *Trop Med Int Health* 11: 115-124.